Sermorelin Does Not Appear to Significantly Affect Blood Sugar or A1C in Diabetic Patients
Based on available evidence, sermorelin (a growth hormone-releasing hormone analogue) does not appear to cause clinically significant changes in blood glucose control or hemoglobin A1c in patients with diabetes. The most relevant study examining this question found no deterioration in glycemic parameters over 12 weeks of treatment 1.
Key Evidence on Sermorelin and Glycemic Control
A randomized, placebo-controlled trial specifically evaluated tesamorelin (a stabilized GHRH analogue similar to sermorelin) in 53 patients with type 2 diabetes over 12 weeks 1. The findings were reassuring:
- No significant changes in fasting glucose between treatment and placebo groups
- No significant differences in HbA1c at 12 weeks
- No alterations in insulin response following oral glucose tolerance testing
- Similar diabetes medication adjustments across all groups
- No patients discontinued due to loss of diabetes control
Importantly, the study tested doses of 1 mg and 2 mg, and even at the higher dose, glycemic control remained stable 1.
Important Mechanistic Considerations
While sermorelin itself appears safe, there's a critical distinction to understand:
Growth hormone (GH) itself can worsen insulin resistance, but sermorelin's effect on GH release appears more physiologic and less problematic than direct GH administration 2. Direct GH therapy has been associated with:
- Increased serum insulin levels (fasting and post-glucose load)
- Rises in fasting blood glucose
- Occasional increases in postprandial glucose and HbA1c
- Rare cases of new-onset impaired glucose tolerance or diabetes
However, these effects are primarily seen with pharmacologic GH administration, not with GHRH analogues like sermorelin that stimulate more physiologic GH pulsatility 2.
Clinical Monitoring Recommendations
Despite the favorable safety profile, prudent monitoring includes:
- Measure HbA1c every 3 months initially when starting sermorelin in diabetic patients, consistent with ADA guidelines for patients with treatment changes 3
- Continue routine glucose monitoring as appropriate for the individual's diabetes management plan
- Watch for any unexpected glycemic excursions in the first 12 weeks, though these appear unlikely based on available data
Critical Caveat
The provided FDA drug label references 4 are for sertraline (an SSRI antidepressant), not sermorelin. This appears to be a data error. Sertraline and sermorelin are completely different medications with different mechanisms and effects. The sertraline information should be disregarded for this question about sermorelin's effects on diabetes.
Bottom Line for Clinical Practice
Sermorelin can be used in diabetic patients without significant concern for worsening glycemic control, based on the 12-week trial data 1. Standard diabetes monitoring protocols should continue, with HbA1c assessment every 3 months during the initial treatment period 3. The theoretical concerns about GH-induced insulin resistance do not appear to manifest clinically with GHRH analogue therapy in the timeframe studied.